[Abstract A direct, simple, and rapid high-performance liquid chromatographic method has been developed for the determination of ethylene-thiourea (ETU) in biological fluids. Samples were chromatographed on a Lichrosorb RP8 (5 pm) column after extraction with dichloromethane. The mobile phase was a mixture of hexane/isopropyl alcohol/ethyl alcohol (93:6:1 v/v) added with 0.6 mL/L butylamine. Detection was done with a UV detector set at 243 nm. This method was validated to standard criteria. Calibration curves for ETU in 100 pL of 0.9% saline, 500 FL plasma, and 10 mL urine were linear (r 2 > 0.99) from 0.05 to 30 pg/mL, 0.025 to 30 pg/mL, and 1 to 100 ng/mL, respectively. The lower limit of detection was 20 ng/mL in plasma, 25 ng/ml_ in 0.9% saline, and 0.5 ng/mL in urine.
Introduction
neurobehavioral effects, including ataxia, hindlimb paralysis, hemiparesis, convulsions, behavioral abnormalities, and neuropathological changes in the brain (7) . Because of this neurotoxicity, it would be useful to be able to determine the concentration of EBDC and/or ETU in cerebrospinal fluid (CSF) and plasma.
Many chromatographic methods have been published to quantitate ETU in foodstuffs (8) , biological fluids (9) , and other substrates using paper and thin-layer chromatography (TLC) (10), gas-liquid chromatography with packed or capillary columns with or without derivatization, and high-performance liquid chromatography (HPLC) (9) (10) (11) . However, most of these methods are not controlled by internal standards and present inadequate reproducibility or insufficient sensitivity for determination of ETU in fluids such as CSE We therefore attempted to devise a method to quantitate ETU in biological fluids.
Ethylenebisdithiocarbamate (EBDC) fungicides are widely used on fruits, vegetables, cereals, and other food crops. Ethylene-thiourea (ETU) is their common degradation product in the environment and their metabolite in plants and animals (1) . It is thought to be the source of most of the toxicity associated with EBDCs.
Although dithiocarbamates are known to display low acute toxicity in humans and in experimental animals (2) , ETU causes hyperplasia and follicular cell neoplasia of the thyroid gland and pituitary gland adenomas induced by a low iodine diet (3) . There is experimental and epidemiological evidence of ETU's potential teratogenicity (4) , carcinogenicity (5) , and genotoxicity (6) .
Chronic use of ethylenebisdithiocarbamate fungicides such as maneh, mancozeb, and zineb may also cause a wide array of Butylamine 99% was of analytical grade from Merck. All organic solvents were distilled-in-glass grade materiel.
Human plasma was obtained from the local blood bank (ETSA, Bordeaux, France). Human urine was obtained from volunteers.
Materials and methods
Standard solution and samples. ETU was purchased as a powder. Stock solution was prepared by dissolving 10 mg ETU powder in 10 mL ethyl alcohol to obtain a concentration of 1 mg/mL. Standard solutions (1, 2.5, 5, 10, 25, 50, and 100 ng/mL, 0.25, 0.5, 1, 2.5, 5, 10, 20, and 30 pg/mL) were prepared by further dilution of the stock solution with appropriate volumes of urine, 0.9% NaCI in water (0.9% saline) or plasma.
The internal standard stock solution of nicotinamide (1 mg/mL) was prepared in ethyl alcohol in the same way.
Standard and stock solutions of ETU and nicotinamide were stored at -20~ Stability of standard stock solution was ascertained as described here.
Apparatus and chrornatographic conditions. The apparatus used for the HPLC analysis was a Millipore Waters 501 pump; a Millipore Waters WISP 710 B autosampler, and a Spectra System iN 100 detector set at 243 nm. Data acquisition and treatment were done with an Omniscribe series D 5000 recorder (Spectra Physics). Separation was carried out at ambient temperature.
The column was a Lichrosorb RP8 (5 p.m) (125-mm column length, 4.6-ram i.d.) (Cil Luzeau, France). The mobile phase was hexane/isopropyl alcohol/ethyl alcohol (93:6:i, v/v) added with 0.6 mUL of butylamine. The flow rate was 1.7 mUmin.
Preparation of samples. In 0.9% saline or cerebrospinal fluid (CSF): 100 lJL of sample (CSF) or standard solution (0.9% saline) was added to 10-mL glass tubes, previously spiked with 100 pL of 25-pg/mL internal standard and 100 mg magnesium sulfate. These were vortex mixed for 30 s. Five milliliters dichloromethane were added, followed by 30 rain agitation. The mixture was then centrifuged at 2000 rpm for 15 rain. The bottom (dichloromethane) layer was transferred to a tube for the dry-down. After evaporation with nitrogen, the dry residue was redissolved in 200 pL of mobile phase. Ten to 100 pL of this volume was injected into the system. The injection volume was chosen according to expected concentration, to avoid system overload.
In plasma (human or rat): sample (rat plasma) or standard solution (human plasma) volume was 500 pL, added to 100 pL of 50-pg/mL IS, 250 mg magnesium sulfate, and 10 mL dichloromethane. Further processing was as described.
In urine: 10 mL standard solution (human urine) was added to the floresil phase of an BondElut | column (12 mL, Interchim, Paris, France). After suction, the column was purged with t mL H20. The sample was recuperated in 20-mL glass tubes and evaporated in a Speed-Vac. The dry residue was redissolved in 2 mL 0.9% saline solution, and ETU was thereafter extracted using the described method with 100 pL of 25-pg/mL internal standard, 500 mg magnesium sulfate, and 20 mL dichloromethane.
Instrument calibration: calibration curves were prepared using standard concentrations of 0.05, 0.1, 0.25, 0.5, 1, 2.5, 5, 10, 20, and 30 pg/mL ETU in 0.9% saline, 0.025, 0.05, 0.1, 0.25, 0.5, 1, 2.5, 5, 10, 20, and 30 pg/mL ETU in plasma and 1, 2.5, 5, 10, 25, 50, and 100 ng/mL ETU in urine.
Validation. Assay performance of the present method was assessed reproducibility for linearity, accuracy, precision, limit of quantitation (LOQ), limit of detection (LOD), and stability.
Precision of the method was tested for within-day and between-day reproducibility. Precision of the method was expressed as [he coefficient of variation [CV% = standard deviation (SD)/mean x 100] of replicate measurements. To be acceptable, this should be less than 10% at all concentrations. This was tested with five concentrations of ETU in 0.9% saline (0.05, 0.1, 0.5, 5, and 30 pg/mL) and plasma (0.025, 0.1, 0.5, 5, and 30 I~g/mL) and four concentrations of ETU in urine (1, 5, 10, and 50 ng/mL). Each sample was analyzed four times on the same day to determine the within-day reproducibility and once daily over six consecutive days to determine between-day reproducibility.
The same data used in the precision determinations was also used to calculate accuracy. Accuracy was expressed as percentage of theoretical value: mean back-calculated concentration/theoretical concentration x 100. Accuracy was deemed acceptable if there was less than 10% difference from expected value.
Linearity was established by building calibration curves in 0.9% salinel plasma, and urine at the ETU concentrations described above in calibrations (0.9% saline, 0.05 to 30 lag/mL; plasma, 0.025 to 30 pg/mL; and urine, 1 to 100 ng/mL).
Each calibration standard was tested on three replicates of each sample for three days in a row. Linear regression analysis of calibration standard data was performed by regressing observed peak-height ratios (ETU/internal standard) on theoretical ETU concentrations in 0.9% saline, plasma, and urine. Slope, intercepts and correlation coefficients were determined and evaluated for linearity.
The equations of calibration curves were y = bx + a. In this model, the independent variables (x) represented the concentration Of ETU in the samples, the dependent variable (y) represented the detector response (height ratios), b was the slope, and a was the y-intercept.
The linearity of the method was confirmed using the linear least-squares regression procedure, by comparing the slopes and the intercepts of calibration curves with zero and correlation coefficients with 1. In addition, the back-calculated to expected concentration ratios were plotted against expected concentration to look for systematic deviation.
The lower LOQ was defined as the lowest drug concentration which could be determined with an accuracy of 80-120% and precision better than 20% (12) . The LOQ was determined by evaluating samples prepared in 100 pL of 0.9% saline at 0.05 ng/mL in 500 pL of human plasma at 0.025 ng/mL, and in 10 mL of human urine at 0.5 ng/mL. During the validation process, the LOQ Samples were analyzed six times.
The lower LOD was considered as being the calibrator concentration below that which qualified as the LOQ if more than three times the baseline noise.
The extraction recovery was determined six times at 0.1, 0.5, and 5 pg/mL of ETU in plasma and 0.9% saline, at 5, 50, and 100 ng/mL in urine, and at the concentration used during the assay for the internal standard. The peak heights obtained after extraction were compared with peaks resulting from the same number of injections of standard solutions in pure ethyl alcohol at the same concentrations in the same volumes.
The stability of ETU and the internal standard in ethyl alcohol was evaluated. Peak height response of stock solutions were determined before storage and re-tested fortnightly for the first month and then monthly for five months.
The stability of ETU in 0.9% saline, human plasma, and human urine in frozen samples (-20~ was determined by comparing the results of repeated analyses of the same samples, every two weeks for two months, to those obtained immediately after initial preparation. Two concentrations were used 0.5 and 5 IJg/mL for the stability studies in plasma and 0.9% saline and 10 and 100 ng/mL in urine. Each determination was performed in triplicate. The drug was considered stable if more than 90% of the intact drug was retained at the end of the study period.
Animal treatment. All animal care and experimentation were performed in approved premises in accordance with national laws and regulations concerning humane treatment of experimental and laboratory animals.
Male rats (200-250 g body weight) were purchased from Charles River (UArbresle, France). Upon arrival, the rats were housed at 22~ temperature, with a 12-h light/dark cycle, for one week before use. Four rats were given an intraperitoneal dose of 25 mg/kg ETU dissolved in 0.25% carboxymethylcellulose, and four rats (control) were given the vehicle alone.
Two hours after ETU or vehicle administration and 20 rain after 1% sodium pentobarbita] anesthesia, CSF and blood were collected according to the protocol described by Suzuki eta] . (13) . The heads of the animals were fixed on a stereotactic apparatus. A 3-in. needle attached to a short length of plastic tubing was inserted into the cisterna magna. CSF was collected in microtubes and examined for blood contamination before freezing at -20~ CSF withdrawal was immediately followed by cardiac puncture. The blood specimens were collected in heparinized tubes and centrifuged at 2500 xg for 15 rain. After centrifugation, the plasma was transferred to another tube before it was frozen at -20~ until analysis.
Results

Chromatography and detection
Under the chromatographic conditions used, ETU and nicotinamide (internal standard) had retention times of 3.36 + 0.06 and 5.00 + 0.04 min, respectively. Representative chromatograms from biological samples (treated rat plasma and CSF) are shown in Figure 2 . There was clear resolution of the compounds of interest (Rs = 4.68) with no interference from endogenous sources.
I_inearity
The ratio of ETU to IS peak heights (y) varied linearly with the corresponding concentrations of ETU (x), over a 0.025 to 30 IJg/mL range in the plasma, 0.05 to 30 pg/mL in 0.9% saline and 1 to 100 ng/mL in urine ( Figure 3A) . Mean equation was y = 0.0035 + 1.182x in 0.9% saline, y = -0.0095 + 1.665x in plasma andy = 0.0041 + 0.0629x in urine. Correlation coefficients of standard curves by least-squares linear regression analysis were > 0.9998, > 0.9997, and >__ 0.9999 for saline, plasma, and urine, respectively. The y-intercepts were not different from zero. For each calibration curve, the sIope was statistically different from 0, as determined by Fisher's test and by Student's test (Table I) .
Plotting the back-calculated to expected concentration ratios against expected concentration showed no systematic deviation ( Figure 3B ).
Accuracy and precision
Assay precision and accuracy were determined by assaying five quality-control samples in 0.9% saline and plasma and four quality-control samples in urine, repeated six times in each matrix. Accuracy was determined by percentage of target value. This was within 10% for all concentrations (Table II) . CV% was always better than 10% except for the LOQ concentration, quantitated with precision better than 20%. Values for the between-day precision were 0.43 to 9.9% in 0.9% saline, 0.79 to 6.96% in plasma, and 0.93 to 3.2% in urine (Table II) . Values for within-day precision varied from 0.74 to 5.32% in 0.9% saline, 0.56 to 4.95% in plasma, and 0.86 to 3.2% in urine (Table II) .
Limits of quantitation and detection
The LOQ of ETU based on acceptable accuracy and precision was 0.05 pg/mL for 100 pL 0.9% saline, 0.025 pg/mL in 500 pL plasma, and 1 ng/mL in 10 mL urine. The mean assay results (n = 6) had CV = 14.3%, 15.8%, and 3.2%, respectively in 0.9% saline, plasma, and urine. The LOD of ETU was 0.025 pg/mL in 0.9% saline, 0.02 pg/mL in plasma, and 0.5 ng/mL in urine.
Extraction recovery
In 0.9% saline (n = 18), mean recovery averaged 101.0 • 4.8% for ETU for the three concentrations pooled (no significant difference between concentrations by ANOVA) and 69.0 • 2.3% for the internal standard. In plasma (n = 18), recoveries were 89.4 • 4.3% for ETU (pooled results) and 53.0 • 3.4% for internal standard. In urine (n = 18), recoveries were 86 • 2.9% for ETU (pooled results) and 49.5 • 3.8% for internal standard. The extraction efficiency was not statistically different over the concentrations studied by one-way ANOVA between concentrations (p = 0.96, 0.73, and 0.86 in 0.9% saline, plasma, and urine, respectively).
Stability
Stock solutions of ETU and internal standard did not reveal any appreciable degradation after six months storage at -20~ The percentage recovery of ETU and internal standard averaged 96.3 • 1.1% and 92 + 2.0%, respectively, after six months storage compared with freshly prepared solutions.
The recovery for 0.5 and 5 pg/mL averaged 93.0 • 2.0% and 91.6 • 1.2% in 0.9% saline, 92.0 • 1.6% and 91.0 • 1% in plasma, and the recovery for 10 and 100 ng/mL averaged 93.5 • 2% and 94 • 3% in urine. Each concentration after two months was compared to initial peak heights. Concentrations of ETU samples stored at -20~ were therefore within 10% of validated values for two months.
Application
This method has been applied to the quantitation of ETU in CSF fluid and plasma. At 2 h the concentration of ETU after administration of 25 mg/kg to rats was 27.4 + 0.3 and 28.4 • 0.4 I~g/mL in CSF and plasma, respectively. In general, ETU is rapidly absorbed from gastrointestinal tract and cleared from the body in all mammalian species (14) with peak concentration at 2 h (15). Though it was validated only in 0.9% saline, plasma, and urine, we believe the method to be valid for CSF, a generally protein-free medium close to 0.9% saline, as well. Moreover, the identical concentration of ETU in plasma and CSF at 2 h is a strong argument for this validity, ETU being a very small, highly diffusible molecule.
Conclusions
This HPLC technique is relatively easy to perform. It conforms with all validation criteria (12) and appears to be reliable in determining ETU in CSF and plasma at the microgram level. This method offers many advantages. Its sensitivity enables the use of small sample volumes of CSF. It is controlled by an internal standard. It can be used to study the pharmacokinetics and CSF penetration of ETU. It can easily be adapted to determination of urinary excretion of ETU, for example to test for exposure to EBDCs. Because of larger sample volumes, ETU in urine can be detected to nanogram levels.
